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mpiric Antiarrhythmic
rug Therapy in Patients
ith Arrhythmogenic
ight Ventricular
ardiomyopathy/Dysplasia
ragmatism or Anachronism?*
. Brent Mitchell, MD
algary, Alberta, Canada
n this issue of the Journal, Marcus et al. (1) present an
bservational study of ventricular tachycardia (VT)/ventricular
brillation (VF) outcomes associated with use of specific
mpiric antiarrhythmic drug (AAD) therapies in a well-
ocumented population of patients with arrhythmogenic right
entricular cardiomyopathy/dysplasia (ARVC/D) from the
rospectively collected North American ARVC Registry. The
RVC/D patients from this registry who had received an
mplantable cardioverter-defibrillator (ICD) were followed up
or the subsequent occurrence of VT/VF. For each analysis,
See page 609
utcomes during periods of time patients received a specific
AD therapy were compared with periods of time that
atients did not receive that AAD therapy and with periods
f time that patients did not receive any AAD therapy using
ime-dependent covariate analyses. The results suggest that
mpiric standard beta-blockers neither increased nor de-
reased follow-up VT/VF (with weak evidence of a decrease
n some analyses), that empiric sotalol did not decrease
ollow-up VT/VF (with more convincing evidence of an
ncrease in some analyses), and that empiric amiodarone
ecreased follow-up VT/VF.
The major strengths of the report are the extent to which
he patients were investigated to define the presence of
RVC/D, the relatively large size of the ARVC/D popu-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiac Sciences, Calgary Health Region and University
f Calgary, and the Libin Cardiovascular Institute of Alberta, Calgary, Alberta,t
anada. Dr. Mitchell is a member of the Advisory Board of Sanofi-Aventis Canada
nd the Adverse Events Committee of Medtronic, Inc.ation studied, and the use of prospectively collected data.
urthermore, this is the first rigorous evaluation of empiric
AD therapy in this setting, and ascertainment of VT/VF
utcomes was maximized by studying patients with ICDs.
The major weaknesses of the report are those inherent
o observational trials, the small numbers of patients with
RVC/D who received each AAD therapy, and the
ubstantial number of comparisons that increase the
robability that an apparently statistically significant
ifference resulted from chance alone. The observational
ature of the study indicates that use of specific AAD
herapies was uncontrolled, raising the possibility that
herapy selection was based on unmeasured factors that
ay have impacted outcomes. For a trial of patients with
RVC/D, the study by Marcus et al. (1) is large.
evertheless, the numbers of patients who received each
AD therapy were small (n  58 for standard beta-
lockers, n  38 for sotalol, and n  10 for amiodarone).
he multiple statistical comparisons question the veracity
f any apparent statistically significant differences. The
tudy population is simply too small to use the standard
tatistical corrections for these multiple comparisons.
Drawing inferences from these results requires consider-
tion of the goals of AAD therapy and previously published
ata from this and other clinical settings.
As with any therapy, use of AAD therapy demands a
lear formulation of the goals of therapy. Relative to AAD
herapies, the dominant goals are prevention of sudden
eath, expecting that achieving this goal will decrease
ll-cause mortality, and prevention of VT/VF. Although
requently concurrent, these 2 goals are not necessarily
ynonymous. There are frequent instances when the
chievement of both goals is impossible, unnecessary, or
nadvisable. When AAD therapy for prevention of VT/VF
as first attempted in patients resuscitated from sustained
T/VF, most of whom had coronary artery disease (CAD)
nd prior myocardial infarction (MI), empiric AAD therapy
that chosen without objective evidence of a beneficial
ntiarrhythmic effect) was not associated with reductions in
T/VF or sudden death (2). Alternatively, AAD therapy
ndividualized for a specific patient by demonstration of an
pparent beneficial effect by either suppression of frequent/
omplex ventricular ectopy or suppression of VT/VF in-
uced by programmed stimulation was suggested to reduce
T/VF occurrences (3,4). However, this advantage has not
een shown to translate into a reduction of sudden death or
ll-cause mortality (5). Empiric amiodarone therapy was an
xception because it was found to decrease both VT/VF and
udden death, although the latter translated only weakly to
reduction in all-cause mortality (6). When the ICD was
hown to be effective for the purpose, ICD implantation
ecame the dominant approach to the prevention of sudden
eath and all-cause mortality in patients with a propensity
o VT/VF and AAD therapies were largely abandoned for
his purpose. However, because current ICDs do not
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August 11, 2009:616–7 Antiarrhythmic Drugs in ARVC/Drevent VT/VF and because ICD therapies for VT/VF may
e both harmful and hurtful, AAD therapy for the goal of
reventing VT/VF and their ICD treatments has had a
esurgence. Empiric AAD therapies are usually used in this
etting. In patient populations dominated by those with
AD and prior MI, evidence of a reduction in ICD
herapies for VT/VF has been reported for empiric treat-
ent with standard beta-blockers (7), sotalol (8), and
miodarone (9). In the study by Marcus et al. (1), only empiric
miodarone was effective in patients with ARVC/D. Of
ourse, these differences may relate to differences in the
atients’ structural heart disease. Nevertheless, these appar-
nt differences may be caused by artifacts. With respect to
tandard beta-blockers, some of the analyses by Marcus et
l. (1) suggest a decrease in follow-up VT/VF, and at least
study, in a population dominated by patients with CAD
nd prior MI, suggested that compared with empiric stan-
ard beta-blockers, empiric sotalol therapy may increase
ubsequent VT/VF (10). Nevertheless, 2 other trials found
hat empiric sotalol therapy neither increased nor decreased
ubsequent VT/VF (9,11). In this regard, it is notable that,
s in patients with CAD and prior MI (12), sotalol therapy
ndividualized by suppression of inducible VT/VF by pro-
rammed stimulation is the single most frequently
redicted-effective AAD therapy and is also effective in
reventing follow-up VT/VF in patients with ARVC/D
13). When sotalol is to be used in this setting with the
trong intent to prevent VT/VF, consideration should be
iven to first predicting its efficacy by the programmed
timulation approach.
In conclusion, Marcus et al. (1) provide us with important
ata regarding the empiric use of AAD therapy in patients
ith ARVC/D. In distinction to patients with CAD and
rior MI, the finding that standard beta-blockers may not
educe the probability of VT/VF in patients with ARVC/D
rgues against its use in all patients. Nevertheless, the
implicity and safety of empiric beta-blocker therapy cou-
led with the suggestion of benefit in some of the analyses
f Marcus et al. (1) recommends that beta-blockers be used
rst when the goal of prevention of VT/VF is established
nless permitting additional episodes of VT/VF is highly
ndesirable. Empiric sotalol therapy is now more difficult to
ecommend, especially when permitting additional episodes
f VT/VF is highly undesirable. It appears that, as in other aettings, the most effective empiric AAD therapy in patients
ith ARVC/D is amiodarone.
eprint requests and correspondence: Dr. L. Brent Mitchell,
oom C822A, Foothills Hospital, 1403 29th Street NW,
algary, Alberta T2N 2T9, Canada. E-mail: brent.mitchell@
lbertahealthservices.ca.
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